Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImaging Bio Regulatory News (IBAI)

Share Price Information for Imaging Bio (IBAI)

Share Price is delayed by 15 minutes
Get Live Data
0.80    0.10 (16.67%)
Bid:
0.60
Ask:
1.00
Spread: 0.40 (66.667%)
Market Cap: £1.73m
IBAI Live PriceLast checked at - London Stock Exchange

Intraday Imaging Bio Share Chart

Expansion Global Distribution Agreement with GE

10 Dec 2025 09:43

RNS Number : 0116L
Imaging Biometrics Limited
10 December 2025
 

December 10, 2025

Imaging Biometrics, Ltd

("IBAI" or the "Company")

 

Imaging Biometrics Expands Global Distribution Agreement with GE HealthCare to Include FTB Express Maps and QSMetric™

 

Imaging Biometrics (IB), a leader in advanced neuroimaging solutions, announces an amendment to its distribution agreement with GE HealthCare, expanding access to two innovative offerings: FTB Express maps and QSMetric.

 

The agreement already includes IB Neuro and Delta T1 maps, widely adopted together to assist clinicians in diagnosing, planning, and monitoring treatment response for brain tumor patients. Delta T1 maps provide rapid, objective delineation of contrast-enhancing regions, while IB Neuro generates standardized (quantitative) MR DSC perfusion images of relative cerebral blood volume (sRCBV), which eliminates manual tissue normalization. These outputs serve as inputs for Fractional Tumor Burden (FTB) maps, which deliver automated visualization of tumor versus non-tumor tissue and treatment effects within enhancing regions. FTB Express accelerates this process, enabling clinicians to quickly access actionable insights for patient care.

 

QSMetric is a patented quantitative susceptibility mapping software that processes gradient echo brain images to visualize tissue structures and measure susceptibility values. This capability supports a broad range of clinical applications, including targeting for deep brain stimulation (DBS) surgery, neurodegenerative disease assessment, multiple sclerosis, and more.

 

Katie Anderson, Global MR Visualization Product Manager at GE HealthCare, said, "We are excited to expand our collaboration with Imaging Biometrics to enable access for our customers to these clinically important capabilities."

 

--ENDS-

 

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

 

Imaging Biometrics Ltd

Trevor Brown/Dr Al Musella/Brett Skelly/Michael Schmainda

Tel: 020 7469 0930

AlbR Capital Limited (Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

 

About Imaging Biometrics® LLCIB is a wholly owned subsidiary of Imaging Biometrics, Ltd, (LON: IBAI), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com. Follow IB on X @ImgBiometrics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRDZMMZLGMGKZG
Date   Source Headline
5th Jun 20267:00 amRNSCommercialisation, Phase II Results & Revenue Path
3rd Jun 202611:30 amRNSResult of AGM
3rd Jun 20267:00 amRNSAGM Statement and Business Update
13th May 20267:00 amRNSAMENDEMENT TO NOTICE OF ANNUAL GENERAL MEETING
12th May 20262:24 pmRNSNOTICE OF ANNUAL GENERAL MEETING
8th May 20267:00 amRNSKIRKSTALL AWARDED BBSRC/NC3Rs GRANT: GLIOBLASTOMA
30th Apr 20264:18 pmRNSAnnual Report for the Year Ended 31 December 2025
19th Feb 202610:48 amRNSBoard Appointment
11th Feb 20267:00 amRNSUpdate and IB Nimble Webinar – 27 February 2026
16th Jan 20267:00 amRNSIBAI: Strategic Direction Fueling Organic Growth
10th Dec 20259:43 amRNSExpansion Global Distribution Agreement with GE
26th Nov 20252:50 pmRNSRelease of Next-Generation IB Clinic
24th Nov 20259:56 amRNSBoard Changes
13th Nov 202511:24 amRNSFractional Tumor Burden Mapping Enhances GBM Trial
10th Nov 20253:14 pmRNSIB Announces Completion of Phase 1 Trial of GaM
16th Oct 20257:00 amRNSFurther Re: Purchase of interest in Kirkstall Ltd
14th Oct 202512:15 pmRNSPurchase of Kirkstall and CLN - Correction
14th Oct 20257:00 amRNSPurchase of Kirkstall and CLN with Truetide plc
3rd Oct 202512:16 pmRNSVivan Therapeutics and IB Announce Partnership
16th Sep 20253:49 pmRNSIB Enters Agreement with MedImageMetric
13th Aug 202511:48 amRNSHalf-year Report
7th Aug 202511:22 amRNSGrant of Share Options
21st Jul 20257:00 amRNSIB Announces Soft Close to Phase 1 Trial
9th Jul 20255:14 pmRNSDirector/PDMR Dealing
12th Jun 202510:30 amRNSIB Provides Update on BTD Application

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.